
医渡科技 12 月通讯 | 2022 年

Yidu Tech Events in December 2022

集团亮点

Business Update

医渡科技旗下 EVYD 股份获现股东增持，赋能公司国际业务拓展

EVYD shares of Yidu Tech were increased by current shareholders, enabling the company to expand its international business

文莱投资局(BIA)旗下投资公司 Yaqut 拟以 5500 万美元增持医渡科技旗下 EVYD 20% 的股份，双方将展开更具战略性的合作，进一步巩固本公司在文莱及海外拓展国际业务的基础，预期其全球网络将更好地赋能公司国际业务拓展。

Yaqut, an investment company of Brunei Investment Authority (BIA), to increase its stake in EVYD, a subsidiary of Yidu Tech, by 20% for US\$55 million. The two companies will enter into a more strategic partnership to further strengthen the company's foundation for international business expansion in Brunei and overseas, which is expected to better enable the company's international business expansion through its global network.

医渡科技旗下开心生活科技出席 DIA 中国年会，以数字化技术守护健康

Happy Life Tech, a subsidiary of Yidu Tech, attended DIA China Annual Meeting to protect health with digital technology

医渡科技集团联合创始人、总经理徐济铭携旗下开心生活科技 (HLT) 多名专家出席中国国际药物信息大会/2022 DIA 中国年会，分享临床研究数字化和智能化的实践与思考。徐济铭介绍，基于“医疗智能大脑”YiduCore，医渡科技从疾病专病库、科研协作平台，到智能化 GCP 解决方案，在研究型医院/研究型病房等政策指引下不断升级，提升医院的数字化竞争力，支撑以患者为中心的数字化临床试验落地。

Xu Jiming, co-founder and general manager of Yidu Tech Group, attended the China International Drug Information Conference/2022 DIA China Annual Meeting with several experts from HLT to share the practice and thinking of digitalization and intelligence of clinical research. Xu Jiming introduced that based on YiduCore, the "Healthcare Intelligence Brain", HLT has been continuously upgraded from disease registry and research collaboration platform to intelligent GCP solutions, under the guidance of policies such as research hospitals/research wards, to enhance the digital competitiveness of hospitals and support the implementation of patient-centered digital clinical trials.



医渡科技受邀参与《WEB3.0 时代医学科研合作与数据共享机制》研讨会

Yidu Tech was invited to participate in the seminar of Medical Research Cooperation and Data Sharing Mechanism in WEB3.0 Era

在以“联邦模式科研合作与数据共享的挑战”为主题的圆桌讨论上，医渡科技首席技术官、首席人工智能科学家闫峻博士表示，Web3.0时代的关注点聚焦在如何使数据产生价值和有效利用上，其中医疗健康领域是Web3.0时代背景下的一个重要分支。医渡科技在实际应用上，已与多家知名三甲医院合作，尤其是在血液肿瘤、眼科领域搭建国家临床医学研究中心平台，助力开展相关领域的多中心临床研究，不断推动数据价值的释放和利用。

In the roundtable discussion themed "Challenges of Federal Model Research Collaboration and Data Sharing", Dr. Yan Jun, Chief Technology Officer and Chief Artificial Intelligence Scientist of Yidu Tech, said that the focus of the Web 3.0 era is on the way to make data valuable and effective, and the healthcare field is an important branch in the Web 3.0 era. In terms of practical application, Yidu Tech has cooperated with many famous 3A hospitals, especially in the field of hematology and oncology and ophthalmology to build a national clinical medical research center platform, to help carry out multi-center clinical research in related fields, and continuously promote the release and utilization of data value.


从 1.0 到 2.0，新一代数据中心 YiduEywa 重磅升级

YiduEywa, a new generation data center, has been upgraded greatly from version 1.0 to version 2.0

YiduEywa2.0 的升级主要体现在数据标准覆盖更全面，数据集成更智能，数据治理更深度，数据服务更便捷，数据安全也更立体几大方面，充分实现“数据分析利用一平台”的目标，从而做到数据统一标准、一次采集、整合共享、多方利用，实现数据分级分类安全的使用。

The upgrade of YiduEywa version 2.0 is mainly reflected in the following aspects: more comprehensive data standard coverage, more intelligent data integration, more in-depth data governance, more convenient data services, and more three-dimensional data security, fully realizing the goal of “one platform for data analysis and utilization”, so as to achieve unified data standard, one-time collection, integration and sharing, and multiple utilization, and realize the use of data classification security.

Eywa 2.0 新一代数据中心



数据统一标准、一次采集、整合共享、多方利用，数据分级分类安全使用



数据分析利用一平台



信息资源管理一张图



数据资源汇聚一个库

业务进展

Business Progress

CAR-T 细胞治疗晚期实体瘤临床研究开展，HLT 提供临床研究服务

Clinical research on CAR-T cell therapy for advanced solid tumors is carried out, with HLT as its clinical research service provider

复旦大学附属肿瘤医院研究者对 LD013 药物开展的一项 IIT 研究正式启动，蓝盾药业提供支持，医渡科技旗下开心生活科技（HLT）提供临床研究服务。LD013 是由蓝盾药业子公司南京蓝盾生物科技有限公司自主研发的 CAR-T 药物，作为蓝盾药业的战略合作伙伴，HLT 助力蓝盾药业的 LD013 自体 T 细胞注射液获得 NMPA 临床试验许可，适应症为复发难治性卵巢癌，为 CAR-T 在实体瘤领域应用开创新征程。

An IIT study of LD013, a drug developed by researchers at the Cancer Hospital of Fudan University, was officially launched with the support of Blue Shield Pharmaceuticals and clinical study services provided by Happy Life Tech (HLT), a subsidiary of Yidu Tech. LD013 is a CAR-T drug independently developed by Blue Shield Pharmaceuticals' subsidiary Nanjing Blue Shield Biotechnology

Co. As a strategic partner of Blue Shield Pharmaceuticals, HLT helped Blue Shield obtain NMPA clinical trial approval for LD013 autologous T-cell injection with the indication of relapsed refractory ovarian cancer, and opens a new journey for CAR-T application in solid tumor field.

HLT 中标某知名药企创新药尿路上皮癌 III 期临床试验项目

HLT won the bid of a well-known pharmaceutical company for the phase III clinical trial project of innovative drug for urothelial carcinoma

医渡科技旗下开心生活科技（HLT）中标某知名药企创新药尿路上皮癌 III 期临床试验项目，客户基于对开心生活科技 II 期项目交付的认可，继续选择 HLT 作为服务商。

Happy Life Tech (HLT), a subsidiary of Yidu Tech, won the bid of a well-known pharmaceutical company for the phase III clinical trial project of innovative drug for urothelial carcinoma. The client continued to choose HLT as its service provider based on its recognition of HLT's phase II project delivery.

医渡云中中标大连医科大学附属第一医院神经疾病区域中心平台等购置项目

YiduCloud won the bid for purchasing projects such as the platform of regional center for neurological diseases of the First Affiliated Hospital of Dalian Medical University

神经疾病区域中心-中心数据库平台，是基于大数据基础和规范化后的全量专病集成数据，建立不同疾病的诊疗模型，支持整体科研流程，系统操作快捷、简便，能够最大程度的支持科研灵感的产生和科研课题的高效完成。

The Regional Center for Neurological Diseases-center database platform, based on the big data base and the full volume of specialized diseases integrated data after normalization, establishes the diagnosis and treatment models of different diseases and supports the overall research process. The system is quick and easy to operate and can support the generation of

scientific inspiration and the efficient completion of research topics to the greatest extent.

2023 年度“北京普惠健康保”参保收官，参保人数超 343 万人

2023 Beijing Puhui Health Insurance enrollment was closed, the number of participants has exceeded 3.43 million.

2022 年 12 月 31 日 24 时，2023 年度“北京普惠健康保”的个人投保通道关闭，总参保人数超 343 万人，相比上一年的 307.3 万人，同比增长 11.6%。医渡科技旗下医渡云作为主运营平台，为 2023 年度“北京普惠健康保”提供技术驱动的全流程运营服务，包括系统搭建、客服、理赔以及数字化营销等。目前，该项目企业团险参保仍在进行中，参保截至 2023 年 1 月 31 日。

At 24:00 on December 31, 2022, the individual payment channel of "2023 Beijing Puhui Health Insurance" was closed, and the total number of participants exceeded 3.43 million, compared with 3.073 million in the previous year, an increase of 11.6% year-on-year. As the main operation platform, YiduCloud, a subsidiary of Yidu Tech, provides technology-driven full process operation services for the "2023 Beijing Puhui Health Insurance", including system construction, customer service, claims processing and digital marketing. At present, the payment channel of enterprise group insurance is still in progress, up to January 31, 2023.

2023 年度“江苏医惠保 1 号”投保本月底截止，参保人数已超 450 万人

2023 Jiangsu Huimin Insurance enrollment ended at the end of this month, the number of participants has exceeded 4.5 million.

为响应市民需求，让‘江苏医惠保 1 号’守护更多人，2023 年度“江苏医惠保 1 号”投保通道延期至 1 月 31 日。截至目前，“江苏医惠保 1 号”已获超 450 万江苏市民投保。医渡科技旗下医渡云为“江苏医惠保 1 号”主运营平台，医渡科

技旗下因数云依托数据智能与医疗健康专业及优势，为“江苏医惠保1号”提供技术驱动的全流程运营服务。

In order to respond to the public demand and let “Jiangsu Huimin Insurance” protect more people, the payment channel of “2023 Jiangsu Huimin Insurance” has been extended to January 31. Up to now, “Jiangsu Huimin Insurance” has served more than 4.5 million Jiangsu citizens. YiduCloud, a subsidiary of Yidu Tech, is the main operation platform of “Jiangsu Huimin Insurance”, and CausaCloud, a subsidiary of Yidu Tech, relies on data intelligence and medical health expertise and advantages to provide technology-driven whole-process operation services for “Jiangsu Huimin Insurance”.

2023 年度“聊惠保”参保收官，超 60 万聊城人保障生效

2023 Liaocheng Huimin Insurance enrollment was closed, coming into effect for the health protection of over 600,000 Liaocheng people

2022 年 12 月 31 日 24 时，2023 年度“聊惠保”投保通道关闭，总参保人数超 60 万。医渡科技旗下健康科技平台和健康保障解决方案提供商因数云作为“聊惠保”项目主运营平台，有力地保障了项目的落地和稳定运营。

At 24:00 on December 31, 2022, the payment channel of “2023 Liaocheng Huimin Insurance” was closed, and the total number of participants exceeded 600,000. As the main operation platform of the “Liaocheng Huimin Insurance” project, CausaCloud, the health technology platform and health security solution provider of Yidu Tech, have effectively guaranteed the landing and stable operation of the project.

集团荣誉

Group Honor

医渡科技“惠民保”项目获评“2022 健康中国创新实践典型案例”

Yidu Tech's Huimin Insurance project was awarded "2022 Health China Typical Case of Innovation Practice"

第二届人民健康大会暨 2022 健康中国创新实践案例征集总结大会在北京举行。

“医渡科技：研发推行‘惠民保’，助力构建多层次医疗保障体系”获得“多元融合”类别的“2022 健康中国创新实践典型案例”。目前，医渡科技已参与了北京、天津、重庆、江苏等 3 省 10 市惠民保项目的开发和运营，累计服务参保用户超 2000 万人，有效地提升了包括老年群体和带病群体在内的广大参保人在面临重大疾病风险时的保障能力。

The 2nd People's Health Conference and 2022 Health China Innovation Practice Case Collection Summary Conference was held in Beijing. "Yidu Tech: R&D and implementation of 'Huimin Insurance', helping to build a multi-level medical security system" won the "2022 Health China Innovation Practice Typical Case". At present, Yidu Tech has participated in the development and operation of the Huimin Insurance project in 3 provinces and 10 cities, including Beijing, Tianjin, Chongqing and Jiangsu, and served more than 20 million insured users in total, effectively enhancing the support ability of insured people, including the elderly and those with illnesses, when they face the risk of major diseases.



医渡科技荣获 2022 年粤港澳大湾区高价值专利培育布局大赛金奖

Yidu Tech won the gold medal in the 2022 Guangdong-Hong Kong-Macao Greater Bay Area High-value Patent Cultivation Layout Competition

2022 年粤港澳大湾区高价值专利培育布局大赛获奖名单正式公布。经过初赛、复赛、决赛的层层角逐，医渡科技新一代电子信息项目从 1057 个参赛项目中脱颖而出，最终荣获大赛金奖。此次获奖，是主办方对医渡科技参赛项目技术领先性、成熟度及发展前景和落地能力的综合认可，也彰显了公司在医疗智能领域核心技术研发、高价值专利培育方面的前瞻布局和实力。

The winners of the 2022 Guangdong-Hong Kong-Macao Greater Bay Area High-Value Patent Cultivation and Layout Competition were officially announced. After competing in the preliminary rounds, semi-finals and finals, Yidu Tech's new generation electronic information project stood out from 1,057 entries and finally won the Gold Award of the competition. This award is a comprehensive recognition of the organizer for the technological leadership, maturity, development prospect and landing ability of Yidu Tech's projects, and also highlights the company's forward-looking layout and strength in core technology R&D and cultivation of high-value patents in the field of healthcare intelligence.

医渡云智脑数据安全管控平台获评 2022 大数据“星河”数据安全优秀案例

The smart brain data security management and control platform of YiduCloud was awarded the excellent case of 2022 big data "Galaxy" data security.

由中国信息通信研究院、中国通信标准化协会大数据技术标准推进委员会 (CCSA TC601) 共同组织的第六届大数据“星河 (Galaxy)”案例征集结果正式公示，“医渡云智脑数据安全管控平台”获评数据安全优秀案例。该平台以数据安全合规、数据防泄露、数据防篡改和数据防滥用为目标，零信任安全为理念，围绕数据全生命周期实现数据安全全方面管理。

The 6th big data "Galaxy" case collection results jointly organized by China Academy of Information and Communication Research and China Communications Standards Association Big Data Technology Standards Promotion Committee (CCSA TC601) was officially announced, and the "Smart Brain Data Security Management and Control Platform" of YiduCloud was awarded as an excellent case of data security. The platform aims at data security compliance, data leakage prevention, data tampering prevention and data abuse prevention, and takes zero-trust security as the concept to realize data security management in all aspects around the whole data life cycle.

医渡科技始终高度重视数据安全及合规，此前还参与了《隐私计算白皮书》《隐私计算应用研究报告（2022年）》等多个行业报告及标准编制工作。

Yidu Tech always attaches great importance to data security and compliance, and has previously participated in the preparation of several industry reports and standards, such as *Privacy Computing White Paper* and *Privacy Computing Application Research Report (2022)*.

医渡科技荣膺 2022 年度卓越科技价值上市公司

Yidu Tech was honored as the 2022 Listed Company with Outstanding Technological Value

由《21世纪经济报道》主办的2022年资本市场「金帆」案例正式发布，医渡科技荣膺“2022年度卓越科技价值上市公司”。自上市以来，医渡科技不断以科技创新加速医疗产业智能化升级，以三大核心业务推动技术价值落地具体场景，助力整体业绩呈现可持续健康增长态势，此次获奖也意味着公司在创新科研能力、市场增长价值、社会价值创造等多方面的高质量发展得到资本市场的认可。

Sponsored by the *21st Century Business Herald*, the "Golden Sail" cases in the capital market in 2022 was officially released, and Yidu Tech was honored as the "2022 Listed Company with Outstanding Technological Value". Since its listing, Yidu Tech has been accelerating the intelligent upgrade of healthcare

industry with technological innovation, promoting the implementation of technological value into specific scenarios with its three core businesses, and helping the overall performance to show sustainable and healthy growth. This award also means that the high-quality development of the company in various aspects such as innovative scientific research capability, market growth value and social value creation has been recognized by the capital market.



医渡科技荣登“2022 中国大健康产业创新上市企业 TOP10”榜单

Yidu Tech won the list of "2022 China TOP10 Innovative Listed Companies in Great Health Industry"

经过为期数月的征集与筛选，通过从企业创新度、应用成熟度、经济价值贡献度等多个维度综合评估，医渡科技成功入选亿欧“2022 中国大健康产业创新上市企业 TOP10”。作为中国医疗智能行业头部企业，医渡科技坚持在技术上自主创新，打造了“医、药、险、患者”医疗产业生态系统，不断推动技术价值落地具体场景，加速医疗产业链各环节的智能化升级。

After months of collection and selection, Yidu Tech was selected by Equal Ocean Health as one of the "2022 China TOP10 Innovative Listed Companies in Great Health Industry" through comprehensive evaluation of enterprise innovation, application maturity, economic value contribution and other

dimensions. As a leading enterprise in China's healthcare intelligence industry, Yidu Tech insists on independent innovation in technology, creates a healthcare industry ecosystem of "healthcare, drugs, insurance and patients", continuously promotes the value of technology into specific scenarios, and accelerates the intelligent upgrade of all links in the healthcare industry chain.



医渡科技荣获第六届中国卓越 IR “最佳股东关系奖”

Yidu Tech won the "Best Shareholder Relationship Award" of 6th China Excellence IR

今年以来, 医渡科技通过线上+线下结合的方式, 积极开展业绩说明会、路演、投资者开放日等交流活动, 帮助投资者全方位了解公司情况, 实现了公司价值的高质量传递, 树立了良好的资本市场形象。卓有成效的股东沟通, 获得了资本市场认可, 未来医渡科技将持续广泛听取资本市场对公司的反馈, 为股东、社会创造更多价值。

Since this year, Yidu Tech has actively carried out communication activities such as performance briefings, roadshows and investor open days through the

combination of online and offline ways, helping investors to understand the company in all aspects, realizing the high-quality transmission of the company's value and establishing a good image of the capital market. The fruitful shareholder communication has been recognized by the capital market. In the future, Yidu Tech will continue to listen to the feedback from the capital market widely to create more value for shareholders and society.



投资者交流

Investor Communication

国泰君安持续看好医渡科技，维持“增持”评级

Guotai Junan continues to be optimistic about Yidu Tech and maintains its hold rating

国泰君安 12 月 9 日发布研报，维持医渡科技增持评级，目标价 11.26 港元。研报中提到，医渡科技仍在加大研发及推广，大数据业务升级推出全病种数据库平

台，生命科学板块不断落地国际 MNC 客户，惠民保服务半径不断扩大，都将为长期发展打好底座，国泰君安看好医渡科技长期发展。

Guotai Junan issued a research report on December 9th, maintaining its hold rating on Yidu Tech with a target price of HK\$11.26. It is mentioned in the research report that Yidu Tech is still increasing its R&D and promotion, upgrading its all-disease database platform in the big data business, cooperating with international MNC customers in the life science segment, and expanding the coverage of Huimin Insurance business, all of which will lay a good base for long-term development. Guotai Junan is optimistic about Yidu Tech's long-term development.

医渡科技位居港股通累计资金净流向总金额前 10%

Yidu Tech ranks in the top 10% of total cumulative net fund flows to Hong Kong Stock Exchange

截至 12 月 31 日，港股通 709 只股票中，医渡科技近 20 日的累计资金净流向总金额排名第 68 名，位居港股通累计资金净流向总金额的前 10%。

As at 31 December, among the 709 stocks on the Hong Kong Stock Exchange, Yidu Tech ranked 68th in terms of total cumulative net capital flows over the past 20 days, placing it in the top 10% of the total cumulative net capital flows on the Hong Kong Stock Exchange.